| Days after vaccination:||84
| Days after onset:||193
|Vaccination / Manufacturer
||Lot / Dose
||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.
||- / 2
||- / IM
Administered by: Unknown Purchased by: Other
Symptoms: Condition aggravated,
Differential white blood cell count normal,
Idiopathic thrombocytopenic purpura,
Mean cell volume normal,
Platelet count decreased,
Red blood cell morphology normal,
White blood cell count normal
SMQs:, Haematopoietic thrombocytopenia (narrow), Haemorrhage terms (excl laboratory terms) (narrow), Systemic lupus erythematosus (broad), Haemorrhagic central nervous system vascular conditions (narrow), Hypersensitivity (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Immune-mediated/autoimmune disorders (narrow)
Life Threatening? No
Birth Defect? No
Date died: 2011-07-06
Days after onset: 96
Permanent Disability? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Other Medications: none
Preexisting Conditions: Immune thrombocytopenic purpura, diagnosed in 1995 and in remission from 2004 to 2011 following treatment with Rituximab in 2004.
Diagnostic Lab Data: Petechiae and ecchymoses noted by patient and family in early April (exact date not known). CBC on 04/26/2011 included platelet count 5000; WBC 5.4 with normal differential, Hgb 12.8, Hct 37.2, MCV 87.9; normal RBC morphology.
CDC Split Type:
Write-up: Relapse of ITP: 18 year-old female with immune thrombocytopenic purpura, diagnosed in 1995 and in remission from 2004 to 2011 following treatment with Rituximab. Relapse in early April, 2011, followed administration of Gardasil vaccine on 10-26-10 and 1-7-11. Relapse of ITP led eventually to death from intracranial hemorrhage on 07/06/2011.